Abstract
Glycemic variability is an important risk factor for metabolic diseases such as diabetes, obesity and cardiovascular diseases, which are closely related to life and diet style. Random eating or eating irregular meals and poor patient compliance with lifestyle changes often happens and makes more difficult to control glycemic variability in life through hypoglycemic drugs around meals. The inhibition of the activity of digestion enzymes in the gut represents an effective strategy for prevention and treatment of glycemic variability. In this study, immune response was employed to induce antibodies (immunoglobulin of egg yolk, IgY) against α-amylase through the subcutaneous injection of α-amylase as the antigen in laying hens. IgY-coupled magnetic nanocomposite hydrogel as α-amylase inhibitor was further developed for long-time against glycemic variability. IgY was covalently coupled to PEG-coated Fe3O4 nanoparticles (PEG/Fe3O4@IgY nanoparticles) and then fabricated by embedding of PEG/Fe3O4@IgY nanoparticles in chitosan-alginate (CS/AS) hydrogels. Under the external magnetic field, lgY-coupled magnetic nanocomposites as α-amylase inhibitors were magnetically anchored in the small intestine for long-time against glycemic variability, resulting in a long-time (>36 h) and effective postprandial hyperglycemia management. This study opens a new door to the health care of the metabolic diseases such as diabetes, obesity and cardiovascular disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.